Literature DB >> 25789770

Gout.

Martin Underwood1.   

Abstract

INTRODUCTION: Gout affects about 5% of men and 1% of women, with up to 80% of people experiencing a recurrent attack within 3 years. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of treatments for acute gout? What are the effects of xanthine oxidase inhibitors to prevent gout in people with prior acute episodes? We searched: Medline, Embase, The Cochrane Library, and other important databases up to September 2013 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 21 studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review, we present information relating to the effectiveness and safety of the following interventions: colchicine, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), and xanthine oxidase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25789770      PMCID: PMC4365763     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  44 in total

Review 1.  Effectiveness of interventions for the treatment of acute and prevention of recurrent gout--a systematic review.

Authors:  S Sutaria; R Katbamna; M Underwood
Journal:  Rheumatology (Oxford)       Date:  2006-04-21       Impact factor: 7.580

Review 2.  The management of gout.

Authors:  B T Emmerson
Journal:  N Engl J Med       Date:  1996-02-15       Impact factor: 91.245

Review 3.  Uric acid and cardiovascular disease: a renal-cardiac relationship?

Authors:  B F Culleton
Journal:  Curr Opin Nephrol Hypertens       Date:  2001-05       Impact factor: 2.894

4.  Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis.

Authors:  Gregory C Borstad; Leslie R Bryant; Michael P Abel; Daren A Scroggie; Mark D Harris; Jeff A Alloway
Journal:  J Rheumatol       Date:  2004-12       Impact factor: 4.666

5.  Efficacy of colchicine prophylaxis in gout. Prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects.

Authors:  T F YU; A B GUTMAN
Journal:  Ann Intern Med       Date:  1961-08       Impact factor: 25.391

6.  Purine-rich foods, dairy and protein intake, and the risk of gout in men.

Authors:  Hyon K Choi; Karen Atkinson; Elizabeth W Karlson; Walter Willett; Gary Curhan
Journal:  N Engl J Med       Date:  2004-03-11       Impact factor: 91.245

7.  Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study.

Authors:  E W Campion; R J Glynn; L O DeLabry
Journal:  Am J Med       Date:  1987-03       Impact factor: 4.965

8.  Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study.

Authors:  Hyon K Choi; Gary Curhan
Journal:  BMJ       Date:  2008-01-31

9.  Allopurinol treatment and its effect on renal function in gout: a controlled study.

Authors:  T Gibson; V Rodgers; C Potter; H A Simmonds
Journal:  Ann Rheum Dis       Date:  1982-02       Impact factor: 19.103

10.  Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout.

Authors:  A Maccagno; E Di Giorgio; A Romanowicz
Journal:  Curr Med Res Opin       Date:  1991       Impact factor: 2.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.